Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Mutations in TP53 and other heterogeneous genes help to distinguish metastases from new primary malignancies

View ORCID ProfileOwen W. J. Prall, Ravikiran Vedururu, Peter Lau, Andrew Fellowes
doi: https://doi.org/10.1101/2020.11.11.20226845
Owen W. J. Prall
1Departments of Pathology, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Owen W. J. Prall
  • For correspondence: owen.prall@petermac.org
Ravikiran Vedururu
1Departments of Pathology, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Lau
2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Fellowes
1Departments of Pathology, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Distinguishing metastases from new primary malignancies or vice versa is important because misclassification can result in inappropriate management. However, for some cases this distinction can be challenging, particularly for squamous cell carcinomas in which the usual surgical pathology approach, predominantly morphology and immunohistochemistry, are frequently non-contributory. We analysed tumor-associated mutations in order to determine whether they could help with this diagnostic dilemma.

Methods Mutations in specific genes were identified with cBioPortal, a large publically available tumor sequence data set. Genes were selected based upon either their high overall prevalence of mutation, or their inclusion in an in-house tumor sequencing set. Tumor types analysed included various common adenocarcinomas, squamous cell carcinomas from multiple sites, urothelial carcinoma and melanoma. Individual mutations and sets of mutations within gene cohorts were compared by their diversity (or heterogeneity) index, prevalence and cumulative prevalence. We demonstrated the utility of this method by performing in-house sequencing of candidate genes in tumors from three patients for which morphology and immunohistochemistry were unable to distinguish between a metastasis and a new primary malignancy.

Results Sequence data from relatively small cohorts of candidate genes readily identified highly diverse, low prevalence mutation profiles in most common malignancies including squamous cell carcinomas. The diversity index predicted the likelihood of an identical mutation profile occurring in an unrelated tumor. High yield gene cohorts could be predicted based on the primary tumor type. Most cohorts included TP53 due to both its high mutation prevalence and high mutation index of diversity. Identical, low prevalence mutations in multiple tumors from patients in the three case studies provided strong diagnostic certainty for metastases rather than new primary malignancies.

Conclusions Most common tumors, including squamous cell carcinomas, have a readily identifiable mutation profiles that occur at a sufficiently low prevalence to effectively barcode or fingerprint the tumor. An identical mutation profile in a primary tumor and a new lesion provides strong evidence for a metastasis and effectively excludes a new primary malignancy, providing diagnostic confidence and aiding clinical management certainty.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No funding was required.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Peter MacCallum Cancer Centre Ethics Committee (approved; project ID #03/90)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data is either publicly available in cBioportal.com or where generated on the 3 case studies is available on request as redacted files.

https://www.cbioportal.org/

  • List of abbreviations

    FFPE
    formalin-fixed paraffin-embedded
    FDG-PET
    fluorodeoxyglucose-positron emission tomography
    CT
    computed-tomography
    PTC
    papillary thyroid carcinoma
    SCC
    squamous cell carcinoma
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
    Back to top
    PreviousNext
    Posted November 16, 2020.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Mutations in TP53 and other heterogeneous genes help to distinguish metastases from new primary malignancies
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Mutations in TP53 and other heterogeneous genes help to distinguish metastases from new primary malignancies
    Owen W. J. Prall, Ravikiran Vedururu, Peter Lau, Andrew Fellowes
    medRxiv 2020.11.11.20226845; doi: https://doi.org/10.1101/2020.11.11.20226845
    Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Citation Tools
    Mutations in TP53 and other heterogeneous genes help to distinguish metastases from new primary malignancies
    Owen W. J. Prall, Ravikiran Vedururu, Peter Lau, Andrew Fellowes
    medRxiv 2020.11.11.20226845; doi: https://doi.org/10.1101/2020.11.11.20226845

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Oncology
    Subject Areas
    All Articles
    • Addiction Medicine (70)
    • Allergy and Immunology (166)
    • Anesthesia (49)
    • Cardiovascular Medicine (448)
    • Dentistry and Oral Medicine (80)
    • Dermatology (55)
    • Emergency Medicine (157)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (188)
    • Epidemiology (5199)
    • Forensic Medicine (3)
    • Gastroenterology (193)
    • Genetic and Genomic Medicine (746)
    • Geriatric Medicine (76)
    • Health Economics (211)
    • Health Informatics (690)
    • Health Policy (350)
    • Health Systems and Quality Improvement (221)
    • Hematology (98)
    • HIV/AIDS (161)
    • Infectious Diseases (except HIV/AIDS) (5793)
    • Intensive Care and Critical Care Medicine (355)
    • Medical Education (101)
    • Medical Ethics (25)
    • Nephrology (80)
    • Neurology (754)
    • Nursing (43)
    • Nutrition (129)
    • Obstetrics and Gynecology (141)
    • Occupational and Environmental Health (230)
    • Oncology (473)
    • Ophthalmology (149)
    • Orthopedics (38)
    • Otolaryngology (93)
    • Pain Medicine (39)
    • Palliative Medicine (19)
    • Pathology (138)
    • Pediatrics (223)
    • Pharmacology and Therapeutics (135)
    • Primary Care Research (96)
    • Psychiatry and Clinical Psychology (851)
    • Public and Global Health (1986)
    • Radiology and Imaging (342)
    • Rehabilitation Medicine and Physical Therapy (154)
    • Respiratory Medicine (282)
    • Rheumatology (93)
    • Sexual and Reproductive Health (72)
    • Sports Medicine (74)
    • Surgery (107)
    • Toxicology (25)
    • Transplantation (29)
    • Urology (39)